lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-14. Numbers and descriptions here follow the published literature rather than marketing material.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
== Neutron crystallography == Hydrogen–deuterium exchange of fast-exchanging species (e.g. hydroxyl groups) can be measured at atomic resolution quantitatively by neutron crystallography, and in real time if exchange is conducted during the diffraction experiment. High intensity neutron beams are generally generated by spallation at linac particle accelerators such as the Spallation Neutron Source. Neutrons diffract crystals similarly to X-rays and can be used for structural determination. Hydrogen atoms, with between one and zero electrons in a biological setting, diffract X-rays poorly and are effectively invisible under normal experimental conditions. Neutrons scatter from atomic nuclei, and are therefore capable of detecting hydrogen and deuterium atoms. Hydrogen atoms are routinely replaced with deuterium, which introduce a strong and positive scattering factor. It is often sufficient to replace only the solvent and labile hydrogen atoms in a protein crystal by vapor diffusion. In such a structure the occupancy of an exchangeable deuterium atom in a crystal will refine from 0-100%, directly quantifying the amount of exchange.
Effective dose at rest and adenosine-induced pharmacologic stress is equal to 0.019 mSv/MBq,; under exercise-induced stress, it is equal to 0.016 mSv/MBq. Whole-body effective dose is described as follows:
Trends in obesity prevalence show no increase among youth since 2003–2004, but trends do show increases in both adults and youth from 1999 to 2000 through 2013–2014. No significant differences between 2011 and 2012 and 2013–2014 were seen in either youth or adults. Under pressure from parents and anti-obesity advocates, many school districts moved to ban sodas, junk foods, and candy from vending machines and cafeterias. State legislators in California, for example, passed laws banning the sale of machine-dispensed snacks and drinks in elementary schools in 2003, despite objections by the California-Nevada Soft Drink Association. The state followed more recently with legislation to prohibit their soda sales in high schools starting July 1, 2009, with the shortfall in school revenue to be compensated by an increase in funding for school lunch programs. A similar law passed by the Connecticut General Assembly in June 2005 was vetoed by governor Jodi Rell, who stated the legislation "undermines the control and responsibility of parents with school-aged children." In mid-2006, the American Beverage Association (including Cadbury, Coca-Cola, and PepsiCo) agreed to a voluntary ban on the sale of all high-calorie drinks and all beverages in containers larger than 8, 10 and 12 ounces in elementary, middle and high schools, respectively. There have been many strategies to try to control obesity issues. One cost-effective population-level change is taxes on sugary drinks. Interventions such as taxes can be a powerful way to improve the economic landscape of the food environment.
Sources: en.wikipedia.org
Fine structure of taste buds in the barbel of the catfish, Ictalurus punctatus. Cell Tissue Res 169, 395–403. Hawkins, M. B. (n.d.). The development and evolutionary origin of barbels in the channel catfish Ictalurus punctatus (Siluriformes: Ictaluridae). 48. Joyce, E. C. and Chapman, G. B. (1978). Fine structure of the nasal barbel of the channel catfish, Ictalurus punctatus. Journal of Morphology 158, 109–153. Kapoor, B. G., Evans, H. E., & Pevzner, E. A. (1976). The Gustatory System in Fish. In Advances in Marine Biology (Vol. 13, pp. 53–108). Elsevier. https://doi.org/10.1016/S0065-2881(08)60280-1 LeClair, E.E. and Topczewski, J. (2009). Methods for the study of the zebrafish maxillary barbel. J Vis Exp, http://www.jove.com/video/1558/methods-for-the-study-of-the-zebrafish-maxillary-barbel?id=1558, doi:10.3791/1558. LeClair, E.E. and Topczewski, J. (2010). Development and regeneration of the zebrafish maxillary barbel: a novel study system for vertebrate tissue growth and repair. PLoS One 5, e8737. McCormick, M. I. (1993). Development and changes at settlement in the barbel structure of the reef fish, Upeneus tragula (Mullidae). Environmental Biology of Fishes, 37(3), 269–282. https://doi.org/10.1007/BF0000463 Ogawa, K., Marui, T. and Caprio, J. (1997). Bimodal (taste/tactile) fibers innervate the maxillary barbel in the channel catfish. Chem Senses 22, 477–82. von der Emde, G., Mogdans, J., & Kapoor, B. G. (Eds.). (2004). The Senses of Fish. Springer Netherlands.
=== Cor–Cz === Robert Corey (1897–1971). American protein chemist at Caltech, known for work with Linus Pauling on the α-helix and β-sheet. Member Natl. Acad. Sci. USA. Carl Ferdinand Cori (1896–1984). American biochemist at Washington University and Albert Einstein College of Medicine, who worked on glycogen. Nobel Prize in Physiology or Medicine (1947). Member Natl. Acad. Sci. USA. Gerty Cori (1896–1957). Czech-American biochemist at Washington University, known for glycogen research. Nobel Prize in Physiology or Medicine (1947). Athel Cornish-Bowden (b. 1943). British enzymologist at the CNRS, Marseille. He has contributed to the development of metabolic control analysis, and is the author of Fundamentals of Enzyme Kinetics. Suzanne Cory (b. 1942). Australian molecular biologist known fotr work on the genetics of the immune system, at the Walter and Eliza Hall Institute of Medical Research, Melbourne. Peter Coveney (b. 1958). British Computational molecular biology specialist at University College London, University of Amsterdam and Yale. Nicholas R. Cozzarelli (1938–2006). American biochemist at UC Berkeley, and former editor-in-chief of the Proceedings of the National Academy of Sciences. Member Natl. Acad. Sci. USA. Gerald Crabtree (b. 1946). American biochemist at Stanford, known for defining the Ca2+-calcineurin-NFAT signalling pathway, pioneering the development of synthetic ligands for regulation of biological processes. Robert K. Crane (1919–2010).
== Vapor-ion, charge transfer reaction == The analytes are in the vapor phase. This includes breath, odors, VOCs, and other molecules with low volatility that, due to the constant improvements in sensitivity, are detectable in the vapor phase despite their low vapor pressure. Analyte ions are produced via gas-phase chemical reactions, where charging agents collide with the analyte molecules and transfer their charge. In secondary electro-spray ionization (SESI), a nano-electrospray operated at high temperature produces nanodroplets that evaporate very rapidly to produce ions and protonated water clusters that ionize the vapors of interest. SESI is commonly used for the analysis of trace concentrations of vapors being able to detect low volatility species in the gas phase with molecular masses of up to 700 Da.
Sources: en.wikipedia.org
Prior to the development of intradialytic parenteral nutrition in the late 20th century, nutritional management of patients receiving dialysis primarily relied on dietary counselling, liberalized renal diets, and oral nutritional supplements; however, protein–energy wasting (PEW) remained common among patients undergoing maintenance hemodialysis. Efforts to supplement nutritional intake by providing nutrients during the dialysis procedure were attempted. As a result, IDPN became an established therapy to threat malnourished CKD stage 5 dialysis patients in the early 1990s. Generally, the patients received a set formulation containing standard amounts of dextrose, amino acids and lipids regardless of the patient's weight, dialysis time, and complicating co-morbid conditions.
In October 2004, an Italian localised edition was launched under the name Videogiochi and published by Future Italy. In December 2006, Future Italy was sold to Sprea Editori which renamed it Game Pro in May 2007. Last issue: September 2009.
Around 1500 BCE a tribe called the Oenotri ("vine-cultivators"), settled in the region. Ancient sources state they were Greeks who were led to the region by their king, Oenotrus. However it is more likely they were an ancient Italic people who spoke an Italic language. During the eighth and seventh centuries BCE, Greeks founded many settlements on the coast of southern Italy. In Calabria they founded Chone (Pallagorio), Cosentia (Cosenza), Clampetia (Amantea), Scyllaeum (Scilla), Sybaris (Sibari), Hipponion (Vibo Valentia), Epizephyrian Locris (Locri), Kaulon (Monasterace), Krimisa (Cirò Marina), Kroton (Crotone), Laüs (comune of Santa Maria del Cedro), Medma (Rosarno), Metauros (Gioia Tauro), Petelia (Strongoli), Rhégion (Reggio Calabria), Scylletium (Borgia), Temesa (Campora San Giovanni), Terina (Nocera Terinese), Pandosia (Acri) and Thurii, (Thurio, comune of Corigliano Calabro). In the year 744 BCE a group of Chalcidian settlers founded Rhegion (today Reggio Calabria) at the southern end of the peninsula. Soon after, other Chalcidans founded Zancle (current Messina) on the other side of the strait, securing their dominion over that arm of the sea. Later Chalcidian settlers from Rhegion and Zancle founded Metauros (Gioia Tauro) and divided the river of the same name (today Petrace) from the Italic city of the Tauri. In 710 BCE Ionian colonists founded Sybaris on the fertile plain of the same name at the mouth of the Crati.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.